The page is the record's research on the issuer — no analyst, no rating, no view. # enGene Therapeutics Inc. (NASDAQ: ENGN) — research page As of 2026-11-08 · us-cm-kg · record version 1 ## Identity and listing The issuer is enGene Therapeutics Inc., listed on NASDAQ under ticker ENGN, with ISIN US29286X1019. Its LEI is not on the record, as no GLEIF record carries the exact legal name in jurisdiction US-Z4. Its security type is Corporate, its segment is not on the record, its sector is 2836 Biological Products, (No Diagnostic Substances), and its jurisdiction is Canada (Federal Level). The issuer is listed and not halted. ## The disclosure read The record holds 67 filings across 33 filing days in the window 2025-11-08 to 2026-11-08. By type, the filings are 2 agm_egm, 8 corporate_news, 3 director_change, 19 directors_dealings, 4 prospectus, 22 regulatory_filing and 9 results. The median gap between filing days is 5.0 days. The latest filing is dated 2026-09-24 and is of type directors_dealings, 45 days before the record date of 2026-11-08. The exchange median is 6.0 days cadence and 5.0 days latency across 4359 issuers, with a median of 52 filings. The sector median is 5.5 days cadence and 4.0 days latency across 176 issuers, with a median of 65.5 filings. ## Auditor The auditor of record is KPMG LLP, located in Montreal, Canada. The record holds no auditor changes. ## Events and halts The record holds no listing, delisting or name change lines. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is listed, not halted. ## Orderability The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04. ## Coverage No research houses were found on the issuer's own investor-relations page, as none was found on the pages read. The count is 0. ## Open research No openly published research notes were found, and the count on the record is 0. ## Licensed Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded. ## As-of depth The issuer's years sealed are 2023, 2024, 2025 and 2026. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12. ## Sources 8 source pages are named on this page; every value above carries its own source page and read date in the numbers. - https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange) - https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin) - https://data.sec.gov/submissions/CIK0001980845.json (identity.jurisdiction) - https://mcp.us-cm-kg.ai/events/NASDAQ/ENGN (the disclosure lines) - https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag) - https://www.sec.gov/Archives/edgar/data/1980845/000119312525328743/engn-20251031.htm (the auditor) - https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter) - https://mcp.us-cm-kg.ai/record/NASDAQ/ENGN (the record) --- Allooloo Technologies Corp. · https://getresearch.ai/us/NASDAQ/ENGN · public-record only · the same page signed and receipted: get_research at https://mcp.getresearch.ai/mcp